Vitamin D autocrine system and prostate cancer.

[1]  M. Hakama,et al.  Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland) , 2000, Cancer Causes & Control.

[2]  M. Holick,et al.  25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  J. McNeal,et al.  Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. , 2001, Cancer research.

[4]  D. Peehl,et al.  Vitamin D and prostate cancer. , 1995, Advances in experimental medicine and biology.

[5]  W. Miller,et al.  Vitamin D 1α-Hydroxylase , 2000, Trends in Endocrinology & Metabolism.

[6]  M. Holick,et al.  Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D3-1alpha-hydroxylase gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D. Feldman,et al.  Liarozole Acts Synergistically with 1α,25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity. , 1999, Endocrinology.

[8]  O. Andrisani.  CREB-mediated transcriptional control. , 1999, Critical reviews in eukaryotic gene expression.

[9]  H. DeLuca,et al.  Current understanding of the molecular actions of vitamin D. , 1998, Physiological reviews.

[10]  T. Stamey,et al.  Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) , 1998, The Journal of urology.

[11]  T. Chen,et al.  Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  K. Burnstein,et al.  Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation. , 1998, Endocrinology.

[13]  H. DeLuca,et al.  Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  W. Miller,et al.  Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. , 1997, Molecular endocrinology.

[15]  H. DeLuca,et al.  Cloning and expression of rat 25-hydroxyvitamin D3-1α-hydroxylase cDNA , 1997 .

[16]  F. Glorieux,et al.  The 25‐Hydroxyvitamin D 1‐Alpha‐Hydroxylase Gene Maps to the Pseudovitamin D‐Deficiency Rickets (PDDR) Disease Locus , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  S. Kato,et al.  25-Hydroxyvitamin D3 1α-Hydroxylase and Vitamin D Synthesis , 1997 .

[18]  R. Day,et al.  Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. , 1995, Urologic oncology.

[19]  D. Peehl,et al.  Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. , 1995, Endocrinology.

[20]  M. Holick,et al.  The antiproliferative and differentiative activities of 1,25-dihydroxyvitamin D3 are potentiated by epidermal growth factor and attenuated by insulin in cultured human keratinocytes. , 1995, The Journal of investigative dermatology.

[21]  R. Bahnson,et al.  Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. , 1994, Anticancer research.

[22]  T. Stamey,et al.  Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. , 1994, Cancer research.

[23]  D. Peehl,et al.  Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. , 1993, Endocrinology.

[24]  M. Lucia,et al.  The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. , 1992, Cancer research.

[25]  Schwartz Gg,et al.  Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). , 1990 .

[26]  J. Delmez,et al.  Extrarenal production of calcitriol. , 1990, Kidney international. Supplement.

[27]  D. Bikle,et al.  Neonatal human foreskin keratinocytes produce 1,25-dihydroxyvitamin D3. , 1986, Biochemistry.